Alivus Life Sciences Ltd

Alivus Life Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Alivus Life Sciences Ltd

₹ 950 2.34%
20 Mar - close price
glenmarklifesciences.com BSE: 543322 NSE: ALIVUS
About

Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.

Key Points

History
Before 2019 API business was an integral part of Glenmark Pharma (GPL). It was separated from GPL into GLS through a Business Transfer Agreement in Jan 2019, and GLS was subsequently listed on NSE & BSE in FY22. [1]

Website BSE NSE
  • Market Cap ₹ 11,658 Cr.
  • Current Price ₹ 950
  • High / Low ₹ 1,225 / 819
  • Stock P/E 33.2
  • Book Value ₹
  • Dividend Yield 0.53 %
  • ROCE %
  • ROE %
  • Face Value ₹ 2.00
Edit ratios

Pros

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE Allcap Nifty Microcap 250 Nifty Total Market Nifty500 Equal Weight

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Operating Profit
OPM %
Interest
Depreciation
Profit before tax
Tax %
EPS in Rs
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021
886 1,537 1,885
639 1,065 1,294
Operating Profit 248 472 591
OPM % 28% 31% 31%
0 12 1
Interest 1 34 88
Depreciation 19 29 33
Profit before tax 228 421 471
Tax % 14% 26% 25%
196 313 352
EPS in Rs 997.86 1,597.37 358.74
Dividend Payout % 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 23%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 12%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 32%
1 Year: -14%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: %

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021
Equity Capital
Reserves
Total Liabilities
CWIP
Investments
Total Assets

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021
Net Cash Flow

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021
Debtor Days
Inventory Days
Days Payable
Cash Conversion Cycle
Working Capital Days
ROCE %

Insights

In beta
Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
R&D Expenditure as percentage of Sales
%

Log in to view insights

Please log in to see hidden values.

Login
Cumulative DMF and CEP Filings
Count
Number of Unique Molecules in API Portfolio
Count
Fixed Assets Turnover Ratio
Times
Total Installed Reactor Capacity
KL
Capacity Utilization
%
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Shareholding Pattern

Numbers in percentages

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
82.85% 82.85% 82.85% 82.85% 82.85% 82.85% 75.00% 75.00% 74.99% 74.94% 74.91% 74.91%
3.28% 3.27% 4.39% 4.57% 5.01% 4.81% 7.85% 6.74% 6.57% 6.42% 6.84% 5.08%
0.00% 0.58% 0.64% 0.74% 1.41% 1.57% 4.16% 4.86% 5.19% 5.62% 5.47% 7.13%
13.86% 13.30% 12.13% 11.84% 10.73% 10.76% 12.99% 13.40% 13.25% 13.03% 12.79% 12.89%
No. of Shareholders 2,22,8662,08,2671,98,7641,85,5311,56,1831,49,3961,43,9601,46,8401,41,9771,38,5001,35,6431,32,748

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls